BIOMAT Database Logo BIOMAT Database Logo

Colonic vasoactive intestinal polypeptide (VIP) in ulcerative colitis--a radioimmunoassay and immunohistochemical study. 1996

V Todorovic, and B Janic, and V Koko, and M Micev, and J A Nikolic, and M Ratkovic, and G Leposavic, and T Jankovic, and S Knezevic-Usaj, and Z Milicevic
Institute for Medical Research, Belgrade, Yugoslavia.

OBJECTIVE In this study, we present radioimmunoassay data describing the concentration of Vasoactive Intestinal Polypeptide (VIP) in both plasma and colonic biopsies, as well as immunostaining of VIPergic innervation in mucosal biopsies of normal subjects and patients with ulcerative colitis (UC). METHODS Thirty three patients with UC and 17 healthy subjects were investigated. All UC patients suffered from active disease. Fasting circulating levels of VIP in plasma as well as tissue concentrations were measured by radioimmunoassay. For the immunohistochemistry, polyclonal antibody against VIP and the streptavidin-biotin peroxidase complex technique were carried out. RESULTS Overall plasma VIP concentrations in the UC patients were similar to those in the controls. Significantly decreased concentrations of VIP were found in UC of rectum compared to the normal tissue. However, both plasma VIP values and tissue concentrations were found to be significantly lower in patients expressing minimal or mild active disease according to clinical activity index (AI) and histological activity index (HAI), but marked increase of plasma VIP was clear in UC patients with moderate or severe AI and HAI. There was a trend towards increased tissue concentrations of VIP in the group of patients with moderate or severe AI and HAI. Our immunohistochemical analysis of VIP fibers and nerve cell bodies revealed consistently weaker VIP-immunoreactivity in the rectum in UC patients with minimal or mild HAI. Simultaneously, in the rectal biopsies from UC patients with moderate and severe disease, the fibers in the lamina propria and ganglion cells in the submucous plexus were markedly increased in density and in degree of immunostaining. Very strong immunoreactivity was also found in inflammatory cells of the lamina propria as well as in the epithelial layer of the biopsies from UC patients with obvious disease. CONCLUSIONS Our study shows clearly the heterogeneity in the response of VIP plasma level as well as rectum concentration and distribution in UC patients at different stages of the active disease. The possible role of VIP in the colon suggests that further studies of the alterations of this gut peptide may be useful in the understanding of UC pathophysiology.

UI MeSH Term Description Entries
D007124 Immunoenzyme Techniques Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens. Antibody Enzyme Technique, Unlabeled,Enzyme Immunoassay,Enzyme-Labeled Antibody Technique,Immunoassay, Enzyme,Immunoperoxidase Techniques,Peroxidase-Antiperoxidase Complex Technique,Peroxidase-Labeled Antibody Technique,Antibody Enzyme Technic, Unlabeled,Enzyme-Labeled Antibody Technic,Immunoenzyme Technics,Immunoperoxidase Technics,Peroxidase-Antiperoxidase Complex Technic,Peroxidase-Labeled Antibody Technic,Antibody Technic, Enzyme-Labeled,Antibody Technic, Peroxidase-Labeled,Antibody Technics, Enzyme-Labeled,Antibody Technics, Peroxidase-Labeled,Antibody Technique, Enzyme-Labeled,Antibody Technique, Peroxidase-Labeled,Antibody Techniques, Enzyme-Labeled,Antibody Techniques, Peroxidase-Labeled,Enzyme Immunoassays,Enzyme Labeled Antibody Technic,Enzyme Labeled Antibody Technique,Enzyme-Labeled Antibody Technics,Enzyme-Labeled Antibody Techniques,Immunoassays, Enzyme,Immunoenzyme Technic,Immunoenzyme Technique,Immunoperoxidase Technic,Immunoperoxidase Technique,Peroxidase Antiperoxidase Complex Technic,Peroxidase Antiperoxidase Complex Technique,Peroxidase Labeled Antibody Technic,Peroxidase Labeled Antibody Technique,Peroxidase-Antiperoxidase Complex Technics,Peroxidase-Antiperoxidase Complex Techniques,Peroxidase-Labeled Antibody Technics,Peroxidase-Labeled Antibody Techniques,Technic, Enzyme-Labeled Antibody,Technic, Immunoenzyme,Technic, Immunoperoxidase,Technic, Peroxidase-Antiperoxidase Complex,Technic, Peroxidase-Labeled Antibody,Technics, Enzyme-Labeled Antibody,Technics, Immunoenzyme,Technics, Immunoperoxidase,Technics, Peroxidase-Antiperoxidase Complex,Technics, Peroxidase-Labeled Antibody,Technique, Enzyme-Labeled Antibody,Technique, Immunoenzyme,Technique, Immunoperoxidase,Technique, Peroxidase-Antiperoxidase Complex,Technique, Peroxidase-Labeled Antibody,Techniques, Enzyme-Labeled Antibody,Techniques, Immunoenzyme,Techniques, Immunoperoxidase,Techniques, Peroxidase-Antiperoxidase Complex,Techniques, Peroxidase-Labeled Antibody
D007413 Intestinal Mucosa Lining of the INTESTINES, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. In the SMALL INTESTINE, the mucosa is characterized by a series of folds and abundance of absorptive cells (ENTEROCYTES) with MICROVILLI. Intestinal Epithelium,Intestinal Glands,Epithelium, Intestinal,Gland, Intestinal,Glands, Intestinal,Intestinal Gland,Mucosa, Intestinal
D008297 Male Males
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D003093 Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. Colitis Gravis,Idiopathic Proctocolitis,Inflammatory Bowel Disease, Ulcerative Colitis Type,Ulcerative Colitis
D003106 Colon The segment of LARGE INTESTINE between the CECUM and the RECTUM. It includes the ASCENDING COLON; the TRANSVERSE COLON; the DESCENDING COLON; and the SIGMOID COLON. Appendix Epiploica,Taenia Coli,Omental Appendices,Omental Appendix,Appendices, Omental,Appendix, Omental
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014660 Vasoactive Intestinal Peptide A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors (RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE). VIP (Vasoactive Intestinal Peptide),Vasoactive Intestinal Polypeptide,Vasointestinal Peptide,Intestinal Peptide, Vasoactive,Intestinal Polypeptide, Vasoactive,Peptide, Vasoactive Intestinal,Peptide, Vasointestinal,Polypeptide, Vasoactive Intestinal

Related Publications

V Todorovic, and B Janic, and V Koko, and M Micev, and J A Nikolic, and M Ratkovic, and G Leposavic, and T Jankovic, and S Knezevic-Usaj, and Z Milicevic
Colonic vasoactive intestinal polypeptide in ulcerative colitis.
January 1993, Journal of physiology, Paris,
V Todorovic, and B Janic, and V Koko, and M Micev, and J A Nikolic, and M Ratkovic, and G Leposavic, and T Jankovic, and S Knezevic-Usaj, and Z Milicevic
Radioimmunoassay of vasoactive intestinal polypeptide (VIP) in plasma.
January 1978, Advances in experimental medicine and biology,
V Todorovic, and B Janic, and V Koko, and M Micev, and J A Nikolic, and M Ratkovic, and G Leposavic, and T Jankovic, and S Knezevic-Usaj, and Z Milicevic
Radioimmunoassay of vasoactive intestinal polypeptide (VIP) in plasma.
June 1977, The Journal of laboratory and clinical medicine,
V Todorovic, and B Janic, and V Koko, and M Micev, and J A Nikolic, and M Ratkovic, and G Leposavic, and T Jankovic, and S Knezevic-Usaj, and Z Milicevic
[Vasoactive intestinal polypeptide (VIP)].
March 1995, Nihon rinsho. Japanese journal of clinical medicine,
V Todorovic, and B Janic, and V Koko, and M Micev, and J A Nikolic, and M Ratkovic, and G Leposavic, and T Jankovic, and S Knezevic-Usaj, and Z Milicevic
[Vasoactive intestinal polypeptide (VIP)].
June 2002, Nihon rinsho. Japanese journal of clinical medicine,
V Todorovic, and B Janic, and V Koko, and M Micev, and J A Nikolic, and M Ratkovic, and G Leposavic, and T Jankovic, and S Knezevic-Usaj, and Z Milicevic
[Vasoactive intestinal polypeptide (VIP)].
December 1999, Nihon rinsho. Japanese journal of clinical medicine,
V Todorovic, and B Janic, and V Koko, and M Micev, and J A Nikolic, and M Ratkovic, and G Leposavic, and T Jankovic, and S Knezevic-Usaj, and Z Milicevic
[Vasoactive intestinal polypeptide (VIP)].
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
V Todorovic, and B Janic, and V Koko, and M Micev, and J A Nikolic, and M Ratkovic, and G Leposavic, and T Jankovic, and S Knezevic-Usaj, and Z Milicevic
[Vasoactive intestinal polypeptide (VIP)].
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
V Todorovic, and B Janic, and V Koko, and M Micev, and J A Nikolic, and M Ratkovic, and G Leposavic, and T Jankovic, and S Knezevic-Usaj, and Z Milicevic
Vasoactive intestinal polypeptide (VIP).
August 1980, Medical biology,
V Todorovic, and B Janic, and V Koko, and M Micev, and J A Nikolic, and M Ratkovic, and G Leposavic, and T Jankovic, and S Knezevic-Usaj, and Z Milicevic
[Vasoactive intestinal polypeptide (VIP)--new radioimmunoassay and its possible clinical applications].
July 1986, Schweizerische medizinische Wochenschrift,
Copied contents to your clipboard!